Compare HOST & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HOST | XLO |
|---|---|---|
| Founded | 2025 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.0M | 56.9M |
| IPO Year | 2023 | 2021 |
| Metric | HOST | XLO |
|---|---|---|
| Price | $2.30 | $8.71 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $18.00 |
| AVG Volume (30 Days) | ★ 465.5K | 13.4K |
| Earning Date | 11-17-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 50.00 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $78,205,678.00 | $43,766,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $11.97 | $23.90 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 12.74 | ★ 589.88 |
| 52 Week Low | $1.48 | $0.46 |
| 52 Week High | $8.99 | $23.80 |
| Indicator | HOST | XLO |
|---|---|---|
| Relative Strength Index (RSI) | 27.34 | 53.99 |
| Support Level | $1.48 | $8.52 |
| Resistance Level | $3.11 | $9.35 |
| Average True Range (ATR) | 0.49 | 0.72 |
| MACD | 0.19 | 0.02 |
| Stochastic Oscillator | 67.68 | 69.96 |
Host Digital Infrastructure LLC is a U.S.-based infrastructure company focused on the development and operation of power-intensive data centers designed to support high-performance computing workloads, including artificial intelligence, data processing, and other compute-intensive applications. The company focuses on securing power resources and deploying computing capacity in regions across the United States.
Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.